Concomitant use of oxycodone HCl with CYP3A4 inducers or discontinuation of the CYP3A4 inhibitor could decrease oxycodone plasma concentrations, minimize opioid efficacy or, quite possibly, bring on a withdrawal syndrome within a patient who experienced formulated Bodily dependence to oxycodone.